Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theragenics on the NYSE (TGX) -- Ignore unavailable to you. Want to Upgrade?

To: Byelow who wrote (292)	1/18/2000 9:48:00 AM
From: bill hopkins	Read Replies (1) \| Respond to of 305

Hi!! Guys..Looks like a fairly good report.. Ratios improving, earnings growth of 40%, possibly some new products..We might do .70 or better this year and have a pretty nice Turnaround on our hands. Is their any reason they couldn't do I-125 if they wanted to?? I think we are going to have a pretty good year!!Congrats Christine..

To: Byelow who wrote (292)	1/19/2000 3:13:00 AM
From: dfloydr	Respond to of 305

Hi Byelow, I posted the following over at the Yahoo thread: Msg: 10988 Report looks good. Best of all recovery is running according to plan. That says more about management than all the squeeling and squaling on this thread over the past year. I'm with you, I did not enjoy this past year either ... but setting out a plan and executing it are two different things in a volatile business environment. TGX has just shown us that they have executed right on schedule. In addition, R&D is stepping up and stepping out into NON-Palladium areas. Oak Ridge is actively being brought in to the picture, and JNJ/Indigo has made Theraseeds the basis for their urology platform. I see the above as offering good prospects for the quarters ahead.